-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only medical professionals can read and refer to clinical information, reachable in 1s ▎Clinical question: How does the 2017 EULAR/ACR classification standard perform in the diagnosis of anti-MDA5 antibody-related idiopathic inflammatory myopathy (IIM)? Screenshot of the literature▎Research protocol: Adult patients clinically diagnosed with anti-MDA5 antibody-related IIM from 10 hospitals in Hong Kong, China were retrospectively recruited
.
Clinical characteristics of all patients were collected from electronic medical records, and myositis-specific autoantibodies (MSA) were detected by western blotting
.
The performance of the 2017 EULAR/ACR classification criteria was tested
.
Anti-MDA5 antibodies were then included in the EULAR/ACR criteria and the MSA-based criteria proposed by Casal-Dominguez et al.
for evaluation, and finally a new set of anti-MDA5-specific phenotype-serological classification criteria was proposed
.
▎Main findings: 120 patients with anti-MDA5-related IIM were recruited, and the subgroups were only dermatomyositis (DM, 31.
7%) and amyopathic dermatomyositis (CADM, 68.
3%)
.
86 (71.
7%) and 49 (40.
8%) patients met EULAR/ACR classification criteria and Bohan & Peter criteria, respectively
.
Adding Sontheimer's CADM criteria, 76.
7% of patients could be classified according to Bohan and Peter criteria
.
If anti-MDA5 antibody is used as one of the criteria, the sensitivity of EULAR/ACR criteria can be increased to 98.
3%
.
The criteria of Casal-Dominguez et al.
had 100% sensitivity in this cohort
.
▎Deficiencies and prospects: Almost 30% of clinical anti-MDA5 antibody-related IIM patients cannot be classified according to EULAR/ACR criteria
.
It is proposed to add anti-MDA5 antibodies to existing criteria or to develop new "anti-MDA5 syndrome" specific criteria
.
The assistant of the top journals of the clinical literature is online👇1.
Scan the QR code below the QR code to jump to the H5 page of "Top Journal Essentials" 2.
Click "Download Now" 3.
Open the Doctor Station App and click the column 4.
Use the clinical medication Find the "Top Issues Essentials" follow column and subscribe to the column, and read a new top issue every day! Download the Doctor Station App and subscribe anytime, anywhere~
